|
市場調查報告書
以生物標記來預測自體免疫疾病生物療法的反應
Special Report: Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases
|
以生物標記來預測自體免疫疾病生物療法的反應 是由出版商Decision Resources, Inc.在2011年06月所出版的。
這份英文市場調查報告書價格從美金9200起跳。
雖然藥劑的安全性與有效性的相關研究仍在持續，但是生物製劑對高價的自體免疫疾病反應預測至今仍是未開發領域。生物標記是能針對最適合的病患施以最適合的療法，顯示標靶治療下患者反應的所有資訊，是可將患者依疾病的嚴重度加以視別的理想媒體。
本報告提供生物療法對自體免疫疾病的使用趨勢，各治療領域的課題與機會，未來的趨勢彙整，為您概述為以下內容。
摘要整理
簡介
生技藥品的複雜性
生物標記和診斷藥的作用
治療領域專門的課題與機會
交易分析
未來的成長相關考察
附註
圖表
Abstract
Introduction:
Despite ongoing research in drug safety and efficacy, even physicians agree
that the ability to predict response to high-priced autoimmune biologics is a
largely untapped field. Biomarkers are the ideal vehicles to elucidate
information about patients who will respond satisfactorily to targeted
therapies and to stratify patients according to disease severity so the most
appropriate treatment can be delivered to the right patients. Will
pharmaceutical and biotechnology companies invest in biomarkers and
biomarker-based companion tests to further enhance the revolutionary value of
biologics?
Questions Answered in This Report:
- Although current biological autoimmune therapies are efficacious, they are
not successful in all patients and can inflict harmful toxicities. How
often are biological agents used as first-line therapies? How can biomarkers
help shed light on how specific patients will respond to biological agents? In
what autoimmune indication do we see the most promise for biomarker-enabled
prescribing?
- Understanding biological pathways and discovering biomarkers are keys to
future success in the autoimmune disease markets. What are the barriers and
opportunities in this arena for more-robust prescribing of biologics? What do
rheumatologists, dermatologists, and gastroenterologists say about the use of
biomarkers and diagnostics for autoimmune/inflammatory diseases?
- An analysis of dealmaking activity shows that large- and
small-capital-backed companies appear to have similar strategic goals when it
comes to use of biomarkers in autoimmune biologics development. What other
strategic trends are revealed for other company types after an analysis of 46
transactions performed across 71 entities over 65 months?
Scope:
- Indications covered: rheumatology (rheumatoid arthritis, ankylosing
spondylitis, osteoarthritis), gastroenterology (Crohn' s disease and ulcerative
colitis), and dermatology (psoriasis and systemic lupus erythematosus).
- Primary research: insight from physician survey of 78 specialists
(27 gastroenterologists, 26 rheumatologists, and 25 dermatologists) that was
fielded by Decision Resources in April 2011; includes data from ongoing
clinical trials as reported in clinicaltrials.gov; additional research
analysis from ChartTrends: Rheumatoid Arthritis 2010, a report by BioTrends
Research Group, a Decision Resources, Inc., company.
- Dealmaking assessment: analysis of 46 deals featuring 71 unique
companies/entities between 2005 and May 2011.
- Exhibits: 18 data-rich tables and figures.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Complex Nature of Biologics
- How Can Biomarkers and Diagnostics Help?
- Therapeutic-Area-Specific Challenges and Opportunities
- Rheumatology
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Osteoarthritis
- Dermatology
- Systemic Lupus Erythematosus
- Psoriasis
- Gastroenterology
- Crohn' s Disease
- Ulcerative Colitis
- Dealmaking Analysis
- Deal Type
- Partnering Companies/Research Institutions
- Considerations for Future Growth
Sidebar
Tables
- 1. Blockbuster Biologics for Autoimmune Diseases, 2010 and 2016
- 2. Autoimmune Diseases Covered in This Report and Select Associated
Biomarkers
- 3. Ongoing and Recently Completed Safety Trials of Biologics for
Autoimmune Diseases
- 4. Autoimmune Biologics-Specific Dealmaking Involving Biomarkers and
Diagnostics, January 2005-May 2011
Figures
- 1. Physician Survey Results: How Biomarkers Can Help Reduce Unmet Needs in
Patients with Autoimmune Disease
- 2. Ongoing Clinical Trials Evaluating Biomarker Activity for Biologics in
Autoimmune Diseases
- 3. Physician Survey Results: Top Two Autoimmune Diseases That Would
Benefit the Most as a Result of Biomarker-Based Diagnostic Tests
- 4. Physician Survey Results: Frequency of Using Biomarker-Based Diagnostic
Tests to Differentially Diagnose Autoimmune Diseases
- 5. Physician Survey Results: Top Three Barriers to Using Biomarkers and
Diagnostics in Diagnosing and/or Managing Autoimmune Diseases
- 6. ChartTrends Results: Correlation Between Common Rheumatoid Arthritis
Biomarkers and Biologics
- 7. Physician Survey Results: Delays in Diagnosis of Rheumatoid Arthritis
- 8. Physician Survey Results: Delays in Diagnosis of Ankylosing Spondylitis
- 9. Physician Survey Results: Delays in Diagnosis of Systemic Lupus
Erythematosus
- 10. Physician Survey Results: Delays in Diagnosis of Inflammatory Bowel
Diseases
- 11. Number of Biomarker and Diagnostics Deals in Autoimmune Disease from
January 2005 Through May 2011
- 12. Number of Biomarker and Diagnostics Deals in Autoimmune Disease from
January 2005 Through May 2011, by Deal Type
- 13. Percentage of Biomarker and Diagnostics Deals in Autoimmune Disease
from January 2005 Through May 2011, by Company Type
- 14. Number of Biomarker and Diagnostics Deals in Autoimmune Disease from
January 2005 Through May 2011, by Company Type
|
